FILTER

FILTERED INTERVIEW RESULTS

Mining
Ghana
MACIG

NanaAma Botchway

MANAGING PARTNER, N. DOWUONA & COMPANY
MACIG 2022
N. Dowuona & Company is a predominantly female-owned and led law firm in Ghana and describes regulatory conditions for mining.
Mining
Niger
MACIG

Stephen G. Roman

PRESIDENT AND CEO, GLOBAL ATOMIC
MACIG 2022
Global Atomic explains progress at its Dasa uranium project in Niger.
Mining
Ghana
MACIG

Seth Asante

MANAGING PARTNER, BENTSI-ENCHILL, LETSA & ANKOMAH (BELA)
MACIG 2022
Ghanian law firm BELA explains recent changes to the country’s mining regulations.
Mining
Cote d’Ivoire
MACIG

Hugh Stuart

CEO, MONTAGE GOLD
MACIG 2022
Montage Gold outlines the potential of its Koné deposit in Ivory Coast.
Mining
Mali
MACIG

Larry Phillips

CEO, COMPASS GOLD
MACIG 2022
Compass Gold explains progress at its Sikasso property in Mali.
Mining
Australia
Cote d’Ivoire
Ghana
Burkina Faso
MACIG

Peter De Leo

MANAGING DIRECTOR, LYCOPODIUM LIMITED
MACIG 2022
Lycopodium is an ASX-listed global engineering and project delivery organisation from Perth, Australia with operations across Africa.
Mining
Mali
MACIG

Bert Monro

CEO, CORA GOLD
MACIG 2022
West African junior Cora Gold updates GBR on progress at Sanankoro, Mali.
Mining
DRC
MACIG

Conrad Karageorge

CEO, AMANI GOLD
MACIG 2022
Amani Gold updates GBR on progress at its Giro gold project in DRC.
Mining
DRC
MACIG

Oliver Dallaway

DIRECTOR DRC, AFRICAN MINING SERVICES (AMS)
MACIG 2022
AMS comments on serving mines and mining contractors in the DRC.
Mining
DRC
MACIG

Olivier Schorochoff & Weid Vereycken

MANAGING DIRECTOR & REGIONAL MANAGER HAUT-KATANGA AND LUALABA, GARDAWORLD
MACIG 2022
GardaWorld is the largest privately-owned security services company in the world, with an annual turnover of around US$4 billion, a total of 120,000 employees.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
MORE PREVIOUSLY PUBLISHED

PARTNER EVENTS

SEE ALL